Vitrolife is the first company in China to receive regulatory approval for an entire IVF culture media portfolio.

Vitrolife is the first company in China to receive regulatory approval
for an entire IVF culture media portfolio.  

Vitrolife is the first company to receive regulatory approval for an
entire IVF culture media portfolio in China. With the approval from
Chinese SFDA (State Food and Drug Administration), Vitrolife can now
provide a unique level of compliance to the IVF community with products
covering all steps of an IVF treatment.

“It has been a long and intense journey to secure that our customers can
work with ease of mind, fulfilling regulatory requirements”. We are very
proud and happy to be the first company to offer approved quality
leading products from retrieval to transfer”, says Dr. Meishan Jin,
Vitrolife's Regional Manager Asia

This approval confirms that Vitrolife brings safe, efficient and
certified products in the hands of IVF professionals.

“China experiences very rapid growth in terms of IVF treatments and
Vitrolife are one of the companies best positioned to take care of that
growth. With this approval, our growth will be further leveraged for the
future, says Dr. Magnus Nilsson, CEO Vitrolife”

During the approval process the company has cooperated closely with
national authorities, to set the quality standard for IVF-products and
secure that customers can work according to Chinese rules and
regulations.

The SFDA approval adds to the list of stringent regulatory approvals of
Vitrolife products for CE-mark, FDA, Canada Health, TGA accompanied by
many local registrations. More information on Vitrolife products and
concepts can be found on www.vitrolife.com

Gothenburg, May 5, 2011

VITROLIFE AB (publ)

Magnus Nilsson

CEO

Queries should be addressed to:

Magnus Nilsson, CEO; phone +46 31 721 80 61

Anne-Lie Sveder, CFO, phone +46 31 721 80 13